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Abstract
Human genetics and immune responses are considered to critically influence the outcome of malaria infections including
life-threatening syndromes caused by Plasmodium falciparum. An important role in immune regulation is assigned to the
apoptosis-signaling cell surface receptor CD95 (Fas, APO-1), encoded by the gene FAS. Here, a candidate-gene association
study including variant discovery at the FAS gene locus was carried out in a case-control group comprising 1,195 pediatric
cases of severe falciparum malaria and 769 unaffected controls from a region highly endemic for malaria in Ghana, West
Africa. We found the A allele of c.2436C.A (rs9658676) located in the promoter region of FAS to be significantly associated
with protection from severe childhood malaria (odds ratio 0.71, 95% confidence interval 0.58–0.88, pempirical=0.02) and
confirmed this finding in a replication group of 1,412 additional severe malaria cases and 2,659 community controls from
the same geographic area. The combined analysis resulted in an odds ratio of 0.71 (95% confidence interval 0.62–0.80,
p=1.8610
27, n=6035). The association applied to c.2436AA homozygotes (odds ratio 0.47, 95% confidence interval 0.36–
0.60) and to a lesser extent to c.2436AC heterozygotes (odds ratio 0.73, 95% confidence interval 0.63–0.84), and also to all
phenotypic subgroups studied, including severe malaria anemia, cerebral malaria, and other malaria complications.
Quantitative FACS analyses assessing CD95 surface expression of peripheral blood mononuclear cells of naı ¨ve donors
showed a significantly higher proportion of CD69
+CD95
+ cells among persons homozygous for the protective A allele
compared to AC heterozygotes and CC homozygotes, indicating a functional role of the associated CD95 variant, possibly in
supporting lymphocyte apoptosis.
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Introduction
Severe malaria caused by infection with the protozoan parasite
Plasmodium falciparum worldwide causes approximately one million
fatalities annually, mostly among children in Sub-Saharan Africa
[1]. The clinical picture of severe malaria is characterized by a
range of distinct but overlapping syndromes including severe
anemia, coma and convulsions, respiratory distress, and others [2].
The variability of the phenotype may be explained by differences
in transmission dynamics and the development of the host’s
immune reactions but also by heritable differences in susceptibility
to the disease [3].
The gene FAS (TNFRSF6, APT1) at chromosome 10q24.1
encodes the cell surface receptor CD95 (Fas, APO-1), known as
the prototypic death receptor [4,5]. CD95 is a widely expressed
molecule with the ability to transduce signals that promote cell
death by apoptosis [6]. The CD95-mediated proapoptotic
function is triggered by its natural ligand, CD95L, which
predominantly is expressed on cells of the T-cell lineage but also
acts in a functional soluble form [7,8]. The CD95/CD95L system
plays a key role in T-cell apoptosis and immune homeostasis as
indicated by the induction of lymphoproliferation and autoimmu-
nity in patients with mutations in either the receptor or its ligand
[9]. In the case of infections with persistent antigenic challenge,
programmed cell death via CD95/CD95L signaling is involved in
the elimination of activated lymphocytes, a process indispensable
to prevent vital tissues from collateral damage caused by
prolonged immune activation [10,11].
Indications for an implication of CD95 during severe malaria
episodes have been gained from several studies. For instance,
lymphocytes from malaria patients were found to express markers
of apoptosis and are susceptible to activation-induced cell death
(AICD) in vitro, and serum samples of patients with P. falciparum
malaria show elevated levels of soluble CD95L as compared to
healthy subjects [12,13]. More specifically, as demonstrated by
Balde and colleagues, the exposure of peripheral blood mononu-
clear cells (PBMC) to P. falciparum extract caused a marked
increase in the expression of functional CD95 [14]. To date, two
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cells from patients with symptomatic malaria have been conducted
[15,16]. In Cameroon, the expression profile in PBMC fractions
was assessed using samples from adults diagnosed for severe
malaria, whereas in a study from Kenya host gene expression was
determined in cells from whole blood derived from acute pediatric
cases. Although major differences exist between the two
experimental designs, both studies detected a significant increase
in the expression of CD95 in circulating blood cells during an
acute falciparum malaria episode. These findings suggest a role for
CD95 in the immune response to infections with P. falciparum,i n
which its precise function has yet to be defined.
In the present study, we sought to elucidate the impact of FAS
genetic variants on malaria susceptibility by conducting a
candidate-gene association study, which involved a variant screen
through re-sequencing and genotyping of selected variants in the
FAS gene in a sample set including 1195 severe malaria cases and
769 apparently healthy controls recruited in Ghana, West Africa.
In addition, the impact of variant c.2436C.A was further
investigated in a replication study from the same geographical
area, including 1412 children with severe malaria and 2659
community controls. With regard to the association of variant
c.2436C.A (rs9658676) with protection from severe malaria in
our study we characterized the allele-dependent CD95 surface
expression of PBMCs by quantitative fluorescence-activated cell
sorting (FACS).
Results
Variants studied
At total of 19 variants were analyzed in the initial case-control
study. Genotypes for 14 of these polymorphisms were derived
using the Affymetrix Genome-Wide Human SNP Array 6.0.
Additional five variants were selected for genotyping after they
were identified by re-sequencing the FAS gene including exonic
and regulatory regions in 46 individuals from our study group.
Among the 16 single nucleotide polymorphisms (SNPs) detected
by re-sequencing, two polymorphisms, c.2671G.A (rs1800682)
in the 59-flanking region and c.46G.A (rs3218619) in exon 1 had
previously been shown to exhibit a substantial effect on the
expression and function of the receptor [17,18]. Hence, both were
selected for genotyping aside from c.365C.T (rs3218614) because
it results in a non-synonymous amino acid exchange (T122I) in the
receptor as well as c.2436C.A (rs9658676) and c.141G.A
(rs3218621) because they showed differences in estimated MAFs
between cases and controls of 0.16 and 0.15, respectively. One
SNP, c.*978C.T, located in the 39-UTR of the gene, was newly
identified. Due to an estimated MAF of 0.02 this SNP was not
selected for genotyping. The SNPs found, their localizations, and
estimated allele frequencies are summarized in Table S1.
Association of FAS variant c.2436C.A with severe
malaria
Genotype frequencies did not deviate from Hardy-Weinberg
Equilibrium (HWE) (p.0.01) except for c.334+46C.T, which in
the case group showed a deviation with p=6.2610
24. When
analysing genotypes in the first case-control sample (n=1964) a
significant result was obtained for the promoter variant
c.2436C.A in the trend test (p=1.3610
23). After adjustment
for multiple testing, the association of c.2436C.A in the logistic
regression analysis remained significant for the additive model of
inheritance (pempirical=0.02) and reached borderline significance
for the dominant model (pempirical=0.05) (Table 1). The A allele of
c.2436C.A was found to be more frequent among controls than
among cases and thus was associated with protection. The odds
ratios (ORs) of c.2436C.A were homogeneous in the three
ethnic groups included in the study group (p=0.92).
The association of c.2436C.A was confirmed in a replication
group of 1412 additional severe-malaria children and 2659
controls (Figure 1). Like in the initial study group, strongest
evidence for association was obtained when applying the additive
inheritance model (OR 0.71, 95% confidence interval (CI) 0.60–
0.83, p=3.1610
25). Combining the results of the two case-control
groups yielded a significance level of p=1.8610
27 (fixed effect
model; OR 0.71, 95% CI 0.62–0.80, Figure 1), with no evidence
for heterogeneity of the effects (p=0.98, Cochran’s Q statistic).
With a combined OR of 0.47 (95% CI 0.36–0.60) c.2436AA
homozygous individuals appear to be protected to a greater
extent than heterozygous individuals (OR 0.73, 95% CI 0.63–
0.84). The data are compatible with an additive inheritance
model (approach of Bagos, p=0.498), whereas both the
dominant and recessive genetic models were rejected (p=0.044
and p=0.0003, respectively).
With the aim of specifying the association of marker
c.2436C.A with regard to severe malaria pathology, a stratified
analysis for clinically distinct subgroups was carried out. After
combining the results from both study groups ORs for the additive
mode of inheritance were found to be similar for the clinical
subgroups of cerebral malaria, severe anemia, and collectively
other complications independent of sample size differences
(Figure 1). Combined ORs ranged from 0.68 for cerebral malaria
cases (95% CI 0.42–0.94, p=1.6610
23;n cases=569) to a
maximum of 0.73 when including cases with complications such
as hyperlactatemia, prostration, and hyperparasitemia collectively
(95% CI 0.58–0.92, p=0.02; ncases=518). The results pointed
towards a protective effect of the A allele in all sub-phenotypes of
severe malaria studied. When analyzing log-transformed parasite
densities in the combined case groups (n=2353), no significant
differences between the three genotypic groups were detected
(p=0.67).
In order to evaluate a possible association of c.2436C.A with
mild malaria, a quantitative transmission disequilibrium test
(qTDT) was performed with the numbers of uncomplicated
Author Summary
Severe malaria caused by infection with the protozoan
parasite Plasmodium falciparum is a major health burden,
causing approximately one million fatalities annually,
predominantly among young children in Sub-Saharan
Africa. The occurrence of severe malaria may depend on
a complex interplay of transmission dynamics and the
development of a protective immune response but also on
heritable differences in the susceptibility to the disease. In
two large studies including a total of 2,607 affected
children and 3,428 apparently healthy individuals from
Ghana, West Africa, we investigated genetic variants of the
FAS gene, which encodes CD95, a molecule critically
involved in the programmed cell death of lymphocytes.
We found that a single nucleotide variant in the FAS
promoter was associated with a 29%–reduced risk of
developing severe malaria. In individuals carrying two
copies of the protective allele, a higher proportion of
activated lymphocytes was found to express CD95. These
findings indicate that a predisposition to an increased
expression of CD95 may help to protect from severe
malaria, possibly by rendering activated T-lymphocytes
more susceptible to programmed cell death.
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period of 31 weeks [19]. No significant distortion of transmission
was found (p=0.96). Likewise, no indication for an association
with peripheral-blood parasite densities was detected when using
the 75th percentile of the siblings’ parasite counts (p=0.55). Given
the clinical and parasitological data, the statistical power to reveal
an influence of c.2436C.A on these two phenotypes was 45%
and 85%, respectively.
Table 1. Logistic regression results for SNPs of the FAS gene locus
a.
SNP ID Positionb MinorAllele
Cases
MAF
Controls
MAF
p-value
c
trend test Additive Model Dominant Model Recessive Model
OR
d
(95% CI
e)
Empirical
p-value
f
OR
d
(95% CI
e)
Empirical
p-value
f
OR
d
(95% CI
e)
Empirical
p-value
f
rs7916294 c.26308 A 0.48 0.47 0.47 1.05 0.99 1.10 0.99 1.03 1
(0.92–1.96) (0.90–1.35) (0.83–1.28)
rs1800682 c.2671 A 0.21 0.22 0.64 0.95 0.99 0.95 1.0 0.92 1
(0.81–1.12) (0.77–1.16) (0.59–1.44)
rs9658676 c.2436 A 0.09 0.12 1.3610
23 0.71 0.02 0.71 0.05 0.43 0.47
(0.58–0.88) (0.56–0.90) (0.19–1.00)
rs10509561 c.30+1249 A 0.21 0.22 0.41 0.94 0.94 0.96 1 0.78 0.98
(0.80–1.09) (0.80–1.16) (0.51–1.19)
rs7097467 c.30+2581 C 0.17 0.16 0.28 1.11 0.96 1.19 0.68 0.71 0.96
(0.93–1.34) (0.97–1.46) (0.39–1.30)
rs7097572 c.30+2597 C 0.17 0.17 0.80 0.98 1 1.01 1 0.71 0.96
(0.82–1.16) (0.83–1.23) (0.42–1.22)
rs1926196 c.30+3085 C 0.17 0.17 0.80 0.98 1 1.02 1 0.69 0.91
(0.82–1.16) (0.84–1.24) (0.40–1.18)
rs9658702 c.31-5541 A 0.14 0.15 0.63 0.95 1 0.96 1 0.82 1
(0.79–1.15) (0.78–1.18) (0.44–1.53)
rs3218619 c.46 A 0.14 0.15 0.84 1.03 1 1.04 1 0.94 1
(0.86–1.23) (0.85–1.28) (0.47–1.84)
rs3218621 c.141 A 0.11 0.11 0.29 0.90 0.97 0.90 0.98 0.80 1
(0.74–1.10) (0.73–1.12) (0.38–1.67)
rs9658733 c.196+338 T 0.15 0.13 0.12 1.15 0.77 1.14 0.93 1.63 0.91
(0.96–1.39) (0.93–1.40) (0.81–3.3)
rs2296601 c.334+46 T 0.19 0.18 0.39 1.08 1 0.98 1 2.2 0.04
(0.91–1.28) (0.80–1.20) (1.29–3.8)
rs3218614 c.365 T 0.05 0.06 0.56 0.91 0.92 0.87 0.99 NA NA
(0.81.28) (0.65–1.17)
rs2234978 c.642 C 0.32 0.34 0.21 0.92 0.94 0.92 0.99 0.84 0.98
(0.80–1.05) (0.77–1.10) (0.63–1.12)
rs1468063 c.*1084 T 0.22 0.20 0.24 1.10 0.94 1.05 1 1.63 0.36
(0.94–1.29) (0.87–1.27) (1.03–2.58)
rs2862833 c.*1422 G 0.46 0.45 0.84 1.01 1 1.05 1 0.96 1
(0.89–1.15) (0.86–1.28) (0.77–1.21)
rs1800623 c.*1876 G 0.33 0.35 0.15 0.91 0.85 0.92 0.99 0.81 0.82
(0.79–1.04) (0.77–1.11) (0.61–1.07)
rs4934435 c.*2189 G 0.33 0.35 0.15 0.91 0.84 0.92 0.99 0.81 0.84
(0.79–1.04) (0.76–1.10) (0.61–1.07)
rs7915235 c.*4890 A 0.21 0.19 0.15 1.13 0.8 1.09 0.99 1.63 0.42
(0.96–1.32) (0.90–1.32) (1.01–2.62)
aResults of SNPs are based on genotypes from 1195 cases and 769 controls.
bPosition in Transcript NM_000043.3;
cuncorrected;
dOR, Odds ratio;
eCI, Confidence interval;
fempirical p-value based on 10,000 permutations of case-control status using the maxT procedure.
doi:10.1371/journal.pgen.1002066.t001
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studied
Of the additional 18 variants studies (Table 1), only
c.334+46C.T showed a disease association in the initial case-
control group, pempirical being 0.04. This was seen only under a
recessive model of inheritance. As the significant findings obtained
with c.2436C.A were limited to the assumption of an additive
inheritance mode, the association of c.334+46C.T being of
borderline significance was not pursued further.
Linkage disequilibrium and haplotype analysis
The analysis of the genomic structure at the FAS locus displayed
remarkably low pairwise linkage disequilibria between markers,
particularly in the promoter region. The variant c.2436C.A
shares a maximum r
2-value of 0.20 with c.46G.A, located 12.6 kb
apart in exon 2 of FAS (Figure 2). Towards the 39-end of the gene
correlation between variants increases, especially for non-coding
variants. Within the entire region of approximately 35 kb
frequencies of inferred haplotypes were compared in a score test
adjusted for age, gender, and ethnicity. Score statistics including full
haplotypes with frequencies of .5% did not reveal any significant
association with disease (global p-values: additive model p=0.15,
dominant p=0.32, recessive p=0.45; haplotype-specific results in
Table S2). However, evidence for a haplotypic association was
observed when analyzing sub-haplotypes under the additive and
dominant models, where a haplotype comprising the three alleles
c.2436A, c.30+1249A, and c.30+2581T was found to be associated
with protection from severe malaria (additive global p=0.018,
dominant global p=2.2610
24; Figure S1).
CD95 surface expression of peripheral blood
mononuclear cells
Quantitative differences in CD95 surface expression in terms of
c.2436C.A genotypes were assessed by staining PBMCs for
CD95 from donors of the three genotypic groups. Each PBMC
fraction was double-labeled in order to quantify CD95 expression
on selected cell types, including CD4
+, CD8
+, CD19
+, and CD69
+
cells. Expression levels defined by the median fluorescent intensity
(FI) for CD95
+ cells were similar among the three genotypic
groups for both, the entire PBMC fractions as well as the
differentiated subpopulations (Figure 3). However, when examin-
ing the proportion of cells expressing CD95 on their surfaces,
donors homozygous for the A allele showed a significantly higher
percentage of CD69
+CD95
+ cells than those with heterozygous
c.2436AC genotypes (Mann-Whitney test p=0.027, Hodges-
Lehmann 95% CI 2.5–45.2) or homozygous c.2436CC genotypes
(p=0.048, 95% CI 2.3–47.0) (Figure 3). No difference was found
between the latter two (p=0.978, 95% CI 215.1–19.6).
Discussion
Collectively, our results show that the variant c.2436C.Ai n
the promoter region of the FAS gene was associated with
protection from severe malaria in Ghanaian children. No
differences were found as to the major clinical forms of the
disease. Statistical analyses resulted in an OR of 0.71 for severe
malaria collectively, and ranged between 0.68 and 0.73 for distinct
clinical phenotypes comprising severe malaria anemia, cerebral
malaria, and other forms of severe malaria, which in our study
included hyperlactatemia, prostration, and hyperparasitemia.
It is important to note, however, that the data presented solely
allow the conclusion that c.2436C.A is a marker for a haplotype
containing one or more genetic variants which reduce the risk of
acquiring severe malaria. They do not show that c.2436C.A
itself exerts this function. c.2436C.A is not predicted to directly
affect a transcription factor binding site (TRANSFAC 7.0, http://
www.gene-regulation.com/pub/databases.html). We did not ob-
tain any evidence for additional variants which might be the causal
Figure 1. Forest plot of FAS c.2436.C.A association with severe malaria and sub-phenotypes. Odds ratios were calculated assuming the
additive model of inheritance; symbol sizes represent relative numbers of individuals.
aCombined result for severe malaria anemia with or without
additional complications including cerebral malaria (n=1626).
bCombined result for cerebral malaria with or without additional complications
including severe anemia (n=569).
cSevere malaria complications not including severe anemia or cerebral malaria (hyperlactatemia, 100%; prostration,
83%; hyperparasitemia, 56%; acidosis, 54%; respiratory distress, 27%, n=518).
doi:10.1371/journal.pgen.1002066.g001
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other variants which are linked to c.2436C.A and might have a
stronger association with the phenotypes studied. However, re-
sequencing was limited to 46 individuals and the linkage analyses
were restricted to a sequence segment of 1 kb and to variants with
an MAF of greater than 5%. Therefore, further association signals
could have remained undiscovered and additional efforts are
needed to convincingly identify the causal variant. c.334+46C.T,
an intronic FAS variant which was associated with marginal
significance, was not linked to 2436C.A and followed a
discordant model of inheritance.
A first hint as to the functional effect of the associated genetic
variant came from a FACS analysis of PBMCs. Studying
apparently healthy donors of the same ethnicity as the participants
of the genetic study, the FAS product CD95 was found expressed
on CD69
+ cells of c.2436AA individuals in a substantially higher
proportion of cells than in those from individuals carrying
c.2436CA or c.2436CC. These data appear not to be in full
agreement with the additive gene effect observed in the association
study.
CD69 is a cell surface glycoprotein that is considered to be the
earliest inducible molecule acquired during lymphoid activation. It
is involved in lymphocyte proliferation and functions as a signal-
transmitting receptor in lymphocytes, natural killer (NK) cells, and
platelets [20]. With regard to malaria, in vitro experiments have
shown that CD69 is universally up-regulated on NK cells in
response to live intact P. falciparum-infected erythrocytes [21].
Thus, the FACS data support the notion that individuals
homozygous for the A allele have a higher susceptibility to AICD
through a CD95/CD95L interaction. In this experiment PBMCs
were used which had been isolated from individuals who appeared
healthy by the time their blood was taken. Therefore, it is
conceivable to assume that heterozygous c.2436CA individuals
have a small increase in the baseline CD95
+ cell fraction that was
not detectable in the experiment but, during malaria episodes,
when CD95 expression is up-regulated [15,16], would show an
intermediate phenotype consistent with the additive effect found in
the genetic association study.
Speculating about a possible mechanism underlying the
observed association, it is worth mentioning that in our study
the c.2436C.A variants were not associated with differences in
parasite counts, neither among our patients during a severe
malaria episode nor in a longitudinal observation of 390 Ghanaian
children monitored by weekly examinations over 31 weeks. In this
Figure 2. LD structure at the FAS gene locus. LD pattern is represented by pairwise r
2 values between SNPs with MAF .5% based on genotypes
from 1195 cases and 769 controls. r
2 values (6100) for each comparison are given in the squares. White squares represent r
2 values equal to 0.
Squares that are shades of grey represent r
2 values between 0 and 1.
doi:10.1371/journal.pgen.1002066.g002
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frequency of mild malaria episodes either, although the latter
finding has to be interpreted with caution because of a moderate
power to detect significant differences. Nevertheless, the mechanism
underlying the c.2436C.A association presumably affects the
pathogenesis of the severe forms of malaria. It appears most likely to
assume that an increased expression of CD95 associated with
c.2436AA and possibly c.2436CA facilitates the programmed cell
Figure 3. FAS c.2436C.A dependent surface expression of CD95 on peripheral blood mononuclear cells. CD95 surface expression was
determined in the entire PBMC fraction as well as on CD4
+, CD8
+, CD19
+, and CD69
+ cells from PBMCs of 72 healthy Ghanaian donors. Plots on the left
show the median fluorescence intensity (MFI), plots on the right represent the mean percentage of CD95
+ cells in each fraction of the donors
stratified by c.2436C.A genotype. Horizontal lines indicate the median for each group.
doi:10.1371/journal.pgen.1002066.g003
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protective FAS allele could alleviate immunopathology. As various
studies have shown, immunopathology contributes substantially to
the pathogenesis of severe malaria episodes [22,23]. Several
mechanisms have been proposed to contribute to the pathogenesis
of malaria anemia including both, the destruction and decreased
production of erythrocytes. Host mechanisms involved in the
suppression of erythropoiesis may involve an excessive innate
immune response with a persistent production of proinflammatory
cytokines [24]. It is possible to envisage a role of CD95 in a down-
regulation of cytokine-producing cells through apoptosis, which
may alleviate an inhibition of erythropoiesis. Further studies are
needed to support these hypotheses and to delineate how they apply
to the various forms of malaria complications.
With allele frequencies of 0.12 in the present study population,
0.16 in the Yoruba from Nigeria, and 0.09 in African Americans,
the A allele has exclusively been found in African populations or
those with African ancestry and appears to be absent in Asian and
European populations. It is possible to envisage a benefit for
individuals carrying the A allele in regions endemic for malaria,
which therefore might undergo a positive selection process
maintaining the allele in a population. Supportive evidence for
this evolutionary aspect comes from a genome-wide search for
variants subjected to protozoa-driven selective pressure [25]. In
that study, FAS was identified to be among the genes with at least
one SNP associated with protozoan diversity in 52 human
populations distributed worldwide.
Although the protective A allele may have an advantageous
effect, with a MAF of 0.12 it appears to be maintained at a
relatively low frequency in a population constantly exposed to P.
falciparum infections. It is possible that its beneficial effect during
severe malaria is counterbalanced by an adverse effect of the same
allele in other infections. For instance, in patients with AIDS, a
disease with too much apoptosis, the depletion of CD4
+ T helper
cells has been shown to be mediated by CD95 [26,27]. In that case
the presence of the A allele could lead to a higher apoptosis rate of
these cells causing a more rapid loss of peripheral CD4
+ T helper
cells in these patients.
In summary, our study provides a rationale for a more detailed
functional characterization of the FAS promoter region, in
particular concerning the relevance of the polymorphism
c.2436C.A in gene regulation with respect to P. falciparum
infections. Further analysis of the CD95/CD95L signaling as part
of the immune response to P. falciparum may yield further insights
into the pathogenesis of life-threatening childhood malaria.
Methods
Ethics statement
The studies were approved by the Committee for Research,
Publications and Ethics of the School of Medical Sciences, Kwame
Nkrumah University of Science and Technology, Kumasi, Ghana.
Informed consent was obtained from parents or guardians of all
participants for both case-control study groups, and from both
parents of families after all procedures were explained in the local
language.
Severe malaria case-control sample sets
The present study was carried out in an area highly endemic for
falciparum malaria in the Ashanti Region of Ghana, West Africa.
The first case-control sample set comprised 1195 severe malaria
cases and 769 controls and had previously been subjected to
genome-wide SNP genotyping utilizing the Affymetrix Genome-
Wide Human SNP Array 6.0 (Affymetrix Inc., Santa Clara, USA)
(manuscript in preparation). In the herein presented candidate-
gene study data for SNPs included in the genome-wide chip were
retrieved for the FAS gene locus. In addition, five selected variants
based on sequencing results (see below) were genotyped in the
initial study group.
The second, independent sample set derived from the same
geographical area included 1412 cases and 2659 controls and was
used for the replication of significant results for variant
c.2436C.A (rs9658676) observed in the first study.
See Table 2 for a summarized characterization of the sample
sets.
As previously described, all severe malaria patients were
enrolled at the Komfo Anokye Teaching Hospital, Kumasi,
between 2001 and 2005 in parallel with the ‘‘Severe Malaria in
African Children’’ study [28]. Briefly, children aged between 6
and 120 months were included in the study if their Giemsa-blood
smear was found to be positive for asexual P. falciparum parasites
and either of the following clinical findings was diagnosed: (i) level
of consciousness according to the Blantyre Coma Score (BCS) ,3;
(ii) hemoglobin concentration ,5 g/dl; (iii) lactate concentration
.5 mmol/L [29]. Parasite densities were recorded for 200
leukocytes and calculated assuming a leukocyte count of 8,000
per ml blood [30]. Controls in the initial case-control study
comprised apparently healthy children who were from the same
geographic area and were matched to the case group for age. In
addition to apparently healthy children, the controls in the
replication study included approximately 10% adults from the
same area.
Family-based study
In order to determine the impact of the variant c.2436C.Ao n
P. falciparum density in mild childhood malaria, genotypes from an
additional study with a total of 739 individuals comprising 390
siblings from 147 families were ascertained. DNA samples from
parents and children used here were recruited and prepared as
part of a genome-wide linkage analysis conducted in the Asante
Akim North District, Ashanti region, Ghana [19]. The phenotype
definitions for enrolled children were based on detailed weekly
assessments over a period of 7 months during the raining season in
2002. Following WHO recommendations [31], mild malaria
attacks were defined by either assessing fever (tympanic temper-
ature of .37.7uC), or reported fever within the previous 4 days
and a positive blood smear for asexual forms of P. falciparum. For
each individual, the number of mild malaria episodes during the
31 week observation period was counted, whereby multiple
episodes within 3 weeks were counted as one, as they were
considered as recrudescences. Among the 390 siblings, a total of
504 malaria episodes were counted during the entire follow-up.
Assuming a leukocyte count of 8,000 per ml blood parasite counts
were recorded per 200 leukocytes (if .10 parasites/200 leuko-
cytes) or 500 leukocytes (if #10 parasites/200 leukocytes). With a
median of 32 parasites per ml blood, parasite densities ranged from
0–317,360/ml blood. Due the fact that the median point
prevalence of malaria parasites was 54%, the 75
th percentile of
parasite densities was considered a representative value of parasite
density for each individual.
Variant discovery in FAS regulatory and coding regions
Variants located in the coding regions of the FAS gene were
detected by re-sequencing the 59-UTR, the exons, including
intron/exon boundaries, and the 39-UTR of 46 genomic DNA
samples drawn from study participants. In order to capture
common alleles in the population, 23 DNA samples were selected
from the control group. In addition, 23 genomic DNA samples of
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possibly selected alleles which confer excess risk for severe malaria.
With 23 samples, the probability of observing a variant with a
MAF$0.05 in a study group is 90% even if HWE does not hold
[32].
Genomic DNA samples were amplified by PCR using primers
that captured a 1000 bp region before the transcription start, the
exonic sequences, including 30 bp of their intronic flanking
regions, and 600 bp of the 39-UTR. Oligonucleotides were
designed using the Primer3 web-interface (http://frodo.wi.mit.
edu/primer3/) against the reference sequence (NCBI
NT_030059.13, Transcript NM_000043.3). Sequences of oligo-
nucleotides and PCR conditions are listed in Table S3. After
purifying the amplicons using Sephadex G-50 (Millipore GmbH,
Schwalbach/Ts., Germany), each PCR fragment was subjected to
a sequencing reaction according to the manufactures’ instruction
using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied
Biosystems, Darmstadt, Germany). Electrophoresis was performed
on the ABI PRISM 3100 DNA Analyzer. Assembly of generated
sequences against the reference sequence and SNP detection was
carried out using the SeqScape Software v2.5 (Applied Biosystems,
Darmstadt, Germany). The presence of singletons was validated
by re-sequencing PCR fragments from both ends.
Genotyping FAS variants
Following the re-sequencing procedure detected variants were
evaluated and selected for genotyping in the first case-control
study (n=1964). Selection criteria were an estimated MAF of
$0.05 in at least one of the two groups, cases or controls, in
addition to one of the following attributes. (i) The polymorphism
leads to a non-synonymous amino-acid exchange in the receptor.
(ii) The polymorphism is known to have functional relevance based
on literature entries. (iii) The difference in estimated MAF from
the re-sequencing between cases and controls is .10%. In
agreement with these conditions a set of 5 SNPs, rs1800682,
rs9658676, rs3218619, rs3218621, and rs3218614 were genotyped
in the initial sample set of 1195 severe malaria cases and 769
controls.
In order to extract DNA for genotyping, blood samples were
drawn from all participants. 0.5–1 ml blood was collected into
citrate, and, before subjected to DNA extraction, the granulocyte
fraction obtained from density gradient centrifugation was
preserved in 4-M urea. DNA was extracted according to the
suppliers’ instructions (Nucleo-Mag 96 Blood; Macherey-Nagel,
Du ¨ren, Germany). Prior to genotyping whole-genome amplifica-
tion (WGA) using 10 ng DNA of each sample was conducted
(GenomiPhi HY DNA Amplification Kit, GE Healthcare,
Braunschweig, Germany). SNPs were analyzed by allele-specific
hybridization in a melting curve analysis based on fluorescence
resonance energy transfer (FRET) in a LightTyper device (Roche
Diagnostics, Mannheim, Germany). Oligonucleotides and PCR
conditions can be found in the Table S4.
Genetic data analyses
For individuals part of the genome-wide association (GWA)
study genotypes were retrieved for SNPs that are included in the
Affymetrix SNP chip and are located at the FAS gene locus or
surrounding regions of 10 kb adjacent to start and end of the gene.
These were then merged with genotypes from the LightTyper
platform. Genotypes were called using Birdseed, and standard
quality control procedures comprised the exclusion of (i)
individuals with SNP-call rates below 0.96, (ii) related individuals
with an IBD.12.5% or (iii) individuals with heterozygosity rates
,26% or .31%. The cluster plots of individual SNPs were
verified by visual inspection. SNPs with call rates ,96% were
excluded. As part of the standard quality control for the five
polymorphisms genotyped on the LightTyper platform, individu-
als with more than 50% missing genotypes were excluded, and
SNPs were allowed to have a maximum of 4% missing genotypes.
Hence, a genotypic data set comprising a total of 19 SNPs at the
FAS gene locus (Chr.10: 90,744,325–90,779,097; NCBI human
genome Build 37.1) spanning approximately 35 kb was analyzed
Table 2. Characteristics of severe malaria case-control sample sets.
Median age (months, range) Ethnic group (%)
Akan Northerner Ewe n
Case-control set 1
Severe Malaria 18 (3–108) 65.4 32.4 2.2 1195
Controls 21 (7–117) 69.6 28.3 2.1 769
Cases stratified by major phenotypes
Severe Anemia
a 18 (3–108) 64.3 33.6 2.1 897
Cerebral Malaria
b 21 (5–108) 66.6 31.5 1.9 371
Replication case-control set
Severe Malaria 20 (2–117) 69.8 26.8 3.4 1412
Controls 24 (7–912) 71.1 21.0 7.9 2659
Cases stratified by major phenotypes
Severe Anemia
a 15 (2–114) 73.9 22.7 3.4 729
Cerebral Malaria
b 28 (7–109) 65.7 30.3 4.0 198
Others
c 27 (5–117) 65.4 30.9 3.7 518
aSevere malaria anemia (hemoglobin level ,5 g/dl) with or without additional complications including cerebral malaria;
bCerebral malaria (BCS,3) with or without additional complications including severe anemia;
cSevere malaria complications not including severe anemia or cerebral malaria (hyperlactatemia, 100%; prostration, 83%; hyperparasitemia, 56%; acidosis, 54%;
respiratory distress, 27%).
doi:10.1371/journal.pgen.1002066.t002
FAS Variant Associated with Severe Malaria
PLoS Genetics | www.plosgenetics.org 8 May 2011 | Volume 7 | Issue 5 | e1002066using primarily PLINK v1.07 [33]. For each polymorphism, the
exact test was used to calculate HWE statistics [34]. The Cochran-
Armitage trend test and logistic regression analyses were
performed with additive coding of genotypes for the initial case-
control study. Potential confounding factors, age, sex, and
ethnicity were used as covariates in the logistic regression
framework. In order to account for multiple testing, empirical
significance values were ascertained by using the maxT permu-
tation procedure with 10,000 permutations for each tested model,
specifically for the additive, dominant, and recessive advantage.
Empirical p-values (pempirical),0.05 were considered significant.
After a significant result was obtained, genotypes for variant
c.2436C.A were retrieved in the replication set. We calculated
results in the replication sample set by logistic regression
accordingly and combined the results using the inverse variance
weighted fixed effects model.
For each SNP a partitioning x
2-test for heterogeneity of ORs
based on stratification into ethnic groups was carried out in order
to detect possible population stratification.
The most plausible genetic model for variant c.2436C.A was
selected using the approach of Bagos [35]. Based on a logistic
regression model this approach uses a Wald test in order to test the
null hypothesis of equality of the logORs associated with each
genotype.
Linkage disequilibrium in the gene region was assessed using
Haploview v4.1 for visualization of pairwise r
2 values [36].
Association tests of haplotypes were calculated using the Haplo-
stats package v1.4.4 in R [37] based on genotypes for all 19 SNPs
in the GWA group of individuals (n=1964). Score tests were
carried out on full inferred haplotypes with frequencies .5% for
the additive, dominant and recessive mode of inheritance, as well
as on sub-haplotypes, using a sliding window of three SNPs. Age,
sex, and ethnicity of individuals were used as covariates in the
score statistics.
For variant c.2436C.A, the family-based qTDTs were done
for the number of mild malaria attacks and the 75
th percentile of
parasite density using the orthogonal model implemented in
QTDT v2.5.1 [38]. The power calculations for the qTDT analysis
are based on a MAF of 0.12 and a significance level of 0.05 [39]. It
was estimated that c.2436C.A genotypes accounted for 5% of
variance in the number of malaria episodes and 14% of the
variance in the 75
th percentiles of parasite density.
CD95 surface expression of peripheral blood
mononuclear cells
PBMCs of 72 naı ¨ve adult African individuals from the Ashanti
region in Ghana were investigated for their level of CD95 surface
expression in relation to the c.2436C.A genotype. Prior to
specific antibody-labeling and FACS of cells genotypes for
c.2436C.A for all 72 individuals were gained as described
above. In order to isolate the PBMC fraction from peripheral
blood of donors a 2.5 ml of citrate blood diluted with 2.5 ml
RPMI was subjected to Ficoll gradient centrifugation at 4uC. The
lymphocyte layer was collected and washed twice with RPMI
before PBMCs were stored in freezing medium, RPMI/10% fetal
calf serum (FCS)/10%DMSO/16Penicillin/Strepto-mycin at
280uC for 12 hours and subsequently in liquid nitrogen for
long-term storage.
After thawing cell fractions were washed with RPMI medium
and re-suspended in 2 ml of pre-chilled blocking solution (16PBS/
10% FCS/10% mouse serum). PBMCs were stained with
biotinylated mAb against CD95 (anti-APO-1 IgG1 isotype, P.H.
Krammer, Heidelberg, Germany) as well as with mAbs against
CD4, CD19, CD8, and CD69 (BD Pharmingen, Heidelberg,
Germany) for differentiation of lymphocyte subsets. Biotin-
conjugated mouse IgG1 antibody (BD Pharmingen) was used as
an isotype control. FACS Canto II flow cytometer and FACS-Diva
software (BD Biosciences, San Jose, USA) were used to perform
analyzes of the cells. As cell counts varied significantly with the
donors, a minimum of 10,000 analyzed cells per assay was set for a
sample to be included in the analysis.
The surface expression level of CD95 was assessed in two
different ways, first by directly measuring FI of cells expressing
CD95 and second by defining the percentage of CD95
+ cells in
particular cell fractions. The average percentage of CD95
+ cells
and the median FI of donors were compared among three
genotypic groups of donors (c.2436CC, n=24; AC, n=22; and
AA, n=26) using the Mann-Whitney test at the nominal 5% test-
level together with corresponding Hodges-Lehmann 95% confi-
dence intervals.
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Figure S1 Score statistic global p-values for additive effect of
sub-haplotypes at the FAS gene locus. Haplotypes tested for
association in a sliding window comprising three SNPs.
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Table S1 Variants in regulatory and coding regions of FAS from
genomic DNA of 23 controls and 23 severe malaria cases
identified by re-sequencing.
aPosition in transcript
NM_000043.3.
bAlleles are matched to the forward strand.
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Table S2 Haplotype-specific p-values from score association
tests with severe falciparum malaria based on inferred haplotypes
with frequencies .5% at the FAS locus.
ap-values adjusted for
gender, age, and ethnicity.
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Table S3 Oligonucleotides and PCR conditions for re-sequenc-
ing of regulatory and coding regions of FAS from genomic DNA.
Each reaction mixture contained 10 ng of genomic DNA, 16PCR
Buffer BD, 1 U FIREPol DNA polymerase I (Solis BioDyne,
Estonia), 200 mM of each dNTP, 1 mM of each PCR Primer,
above stated concentration of MgCl2, and water to a final volume
of 20 ml. PCR conditions were as follows: 94uC for 3 min, 40
cycles of 95uC for 1 min, specific annealing temperature for
1 min, 72uC for 1 min followed 72uC for 10 min.
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Table S4 Oligonucleotides and PCR conditions for genotyping
selected FAS variants. Each reaction mixture contained 2 mlo fa
1:200 dilution of whole-genome wide amplified genomic DNA,
16PCR Buffer BD, 16 Solution S, 1 U FIREPol DNA
polymerase I (Solis BioDyne. Estonia), 200 mM of each dNTP,
1 mM or 0.2 mM of each PCR primer, 0.2 mM of each
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(DOC)
Acknowledgments
The authors would like to thank the children, their parents, and guardians
as well as all healthy blood donors who participated in the study. Tsiri
Agbenyega represents the Kumasi team of the Severe Malaria in African
Children (SMAC) network, which includes Sampson Antwi, MD, Emanuel
Asafo-Adjei, MD, Samuel Blay Nguah, MD, Kingsley Osei Kwakye, MD,
Alex Osei Yaw Akoto, MD, and Justice Sylverken, MD, all of Komfo
Anokye Teaching Hospital, Kumasi, Ghana.
FAS Variant Associated with Severe Malaria
PLoS Genetics | www.plosgenetics.org 9 May 2011 | Volume 7 | Issue 5 | e1002066Author Contributions
Conceived and designed the experiments: K Schuldt, CC Kretz, C
Timman, J Evans, J May, PH Krammer, T Agbenyega, RD Horstmann.
Performed the experiments: K Schuldt, CC Kretz, C Ehmen, J Evans, D
Ansong, J Sievertsen. Analyzed the data: K Schuldt, CC Kretz, C
Timman, C Esser, W Loag, C Dering, A Ziegler, RD Horstmann.
Contributed reagents/materials/analysis tools: PH Krammer. Wrote the
manuscript: K Schuldt, A Ziegler, J May, RD Horstmann.
References
1. WHO (2000) Severe falciparum malaria. World Health Organization,
Communicable Diseases Cluster. Trans R Soc Trop Med Hyg 94: S1–90.
2. Marsh K, Forster D, Waruiru C, Mwangi I, Winstanley M, et al. (1995)
Indicators of life-threatening malaria in African children. N Engl J Med 332:
1399–1404.
3. Kwiatkowski DP (2005) How malaria has affected the human genome and what
human genetics can teach us about malaria. Am J Hum Genet 77: 171–192.
4. Behrmann I, Walczak H, Krammer PH (1994) Structure of the human APO-1
gene. Eur J Immunol 24: 3057–3062.
5. Lichter P, Walczak H, Weitz S, Behrmann I, Krammer PH (1992) The human
APO-1 (APT) antigen maps to 10q23, a region that is syntenic with mouse
chromosome 19. Genomics 14: 179–180.
6. Krammer PH (2000) CD95’s deadly mission in the immune system. Nature 407:
789–795.
7. Suda T, Takahashi T, Golstein P, Nagata S (1993) Molecular cloning and
expression of the Fas ligand, a novel member of the tumor necrosis factor family.
Cell 75: 1169–1178.
8. Tanaka M, Suda T, Takahashi T, Nagata S (1995) Expression of the functional
soluble form of human fas ligand in activated lymphocytes. EMBO J 14:
1129–1135.
9. Bidere N, Su HC, Lenardo MJ (2006) Genetic disorders of programmed cell
death in the immune system. Annu Rev Immunol 24: 321–352.
10. Sprent J, Tough DF (2001) T cell death and memory. Science 293: 245–248.
11. Strasser A, Jost PJ, Nagata S (2009) The many roles of FAS receptor signaling in
the immune system. Immunity 30: 180–192.
12. Kemp K, Akanmori BD, Adabayeri V, Goka BQ, Kurtzhals JA, et al. (2002)
Cytokine production and apoptosis among T cells from patients under treatment
for Plasmodium falciparum malaria. Clin Exp Immunol 127: 151–157.
13. Kern P, Dietrich M, Hemmer C, Wellinghausen N (2000) Increased levels of
soluble Fas ligand in serum in Plasmodium falciparum malaria. Infect Immun
68: 3061–3063.
14. Balde AT, Aribot G, Tall A, Spiegel A, Roussilhon C (2000) Apoptosis
modulation in mononuclear cells recovered from individuals exposed to
Plasmodium falciparum infection. Parasite Immunol 22: 307–318.
15. Griffiths MJ, Shafi MJ, Popper SJ, Hemingway CA, Kortok MM, et al. (2005)
Genomewide analysis of the host response to malaria in Kenyan children. J Infect
Dis 191: 1599–1611.
16. Ockenhouse CF, Hu WC, Kester KE, Cummings JF, Stewart A, et al. (2006)
Common and divergent immune response signaling pathways discovered in
peripheral blood mononuclear cell gene expression patterns in presymptomatic
and clinically apparent malaria. Infect Immun 74: 5561–5573.
17. Huang QR, Morris D, Manolios N (1997) Identification and characterization of
polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene.
Mol Immunol 34: 577–582.
18. Jackson CE, Fischer RE, Hsu AP, Anderson SM, Choi Y, et al. (1999)
Autoimmune lymphoproliferative syndrome with defective Fas: genotype
influences penetrance. Am J Hum Genet 64: 1002–1014.
19. Timmann C, Evans JA, Konig IR, Kleensang A, Ruschendorf F, et al. (2007)
Genome-wide linkage analysis of malaria infection intensity and mild disease.
PLoS Genet 3: e48. doi:10.1371/journal.pgen.0030048.
20. Ziegler SF, Ramsdell F, Hjerrild KA, Armitage RJ, Grabstein KH, et al. (1993)
Molecular characterization of the early activation antigen CD69: a type II
membrane glycoprotein related to a family of natural killer cell activation
antigens. Eur J Immunol 23: 1643–1648.
21. Korbel DS, Newman KC, Almeida CR, Davis DM, Riley EM (2005)
Heterogeneous human NK cell responses to Plasmodium falciparum-infected
erythrocytes. J Immunol 175: 7466–7473.
22. Riley EM, Wahl S, Perkins DJ, Schofield L (2006) Regulating immunity to
malaria. Parasite Immunol 28: 35–49.
23. Schofield L, Grau GE (2005) Immunological processes in malaria pathogenesis.
Nat Rev Immunol 5: 722–735.
24. McDevitt MA, Xie J, Gordeuk V, Bucala R (2004) The anemia of malaria
infection: role of inflammatory cytokines. Curr Hematol Rep 3: 97–106.
25. Pozzoli U, Fumagalli M, Cagliani R, Comi GP, Bresolin N, et al. (2010) The role
of protozoa-driven selection in shaping human genetic variability. Trends Genet
26: 95–99.
26. Debatin KM, Fahrig-Faissner A, Enenkel-Stoodt S, Kreuz W, Benner A, et al.
(1994) High expression of APO-1 (CD95) on T lymphocytes from human
immunodeficiency virus-1-infected children. Blood 83: 3101–3103.
27. Westendorp MO, Frank R, Ochsenbauer C, Stricker K, Dhein J, et al. (1995)
Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120.
Nature 375: 497–500.
28. May J, Evans JA, Timmann C, Ehmen C, Busch W, et al. (2007) Hemoglobin
variants and disease manifestations in severe falciparum malaria. JAMA 297:
2220–2226.
29. WHO (2000) Severe falciparum malaria. World Health Organization,
Communicable Diseases Cluster. Trans R Soc Trop Med Hyg 94(Suppl 1):
S1–90.
30. Taylor T, Olola C, Valim C, Agbenyega T, Kremsner P, et al. (2006)
Standardized data collection for multi-center clinical studies of severe malaria in
African children: establishing the SMAC network. Trans R Soc Trop Med Hyg
100: 615–622.
31. WHO (2000) WHO Expert Committee on Malaria. World Health Organ Tech
Rep Ser 892: i–v1–74.
32. Ziegler A, Koenig, IR (2010) A statistical approach to genetic epidemiology.
Weinheim, Germany: Wiley-VCH.
33. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007)
PLINK: a tool set for whole-genome association and population-based linkage
analyses. Am J Hum Genet 81: 559–575.
34. Wigginton JE, Cutler DJ, Abecasis GR (2005) A note on exact tests of Hardy-
Weinberg equilibrium. Am J Hum Genet 76: 887–893.
35. Bagos PG, Nikolopoulos GK (2007) A method for meta-analysis of case-control
genetic association studies using logistic regression. Stat Appl Genet Mol Biol 6:
Article17.
36. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and
visualization of LD and haplotype maps. Bioinformatics 21: 263–265.
37. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA (2002) Score
tests for association between traits and haplotypes when linkage phase is
ambiguous. Am J Hum Genet 70: 425–434.
38. Abecasis GR, Cardon LR, Cookson WO (2000) A general test of association for
quantitative traits in nuclear families. Am J Hum Genet 66: 279–292.
39. Lange C, DeMeo D, Silverman EK, Weiss ST, Laird NM (2004) PBAT: tools
for family-based association studies. Am J Hum Genet 74: 367–369.
FAS Variant Associated with Severe Malaria
PLoS Genetics | www.plosgenetics.org 10 May 2011 | Volume 7 | Issue 5 | e1002066